Ono Pharmaceutical Co., Ltd.
Notice Regarding Changes in Directors and Executive Officers
Announcement of scheduled reappointment of all six directors as of April 1, 2026, and at the shareholders meeting planned for June 2026, along with changes in executive officers.
Key Figures
- Number of Directors Scheduled for Reappointment: 6 (scheduled for June 2026)
- Effective Date of Executive Officer Changes: 2026-04-01
- Number of Outside Directors Scheduled for Reappointment: 3
AI要約
Overview of Director Personnel Changes
Ono Pharmaceutical Co., Ltd. announced that all six current directors are scheduled for reappointment at the 78th Annual General Shareholders Meeting to be held in June 2026. This includes President and Representative Director Juichi Takino and three outside directors who will continue to serve as directors. This is expected to maintain management stability.
Overview and Impact of Executive Officer Personnel Changes
Executive officer changes will take effect on April 1, 2026. Satoshi Tsujinaka will be appointed as Representative Director and Executive Vice President, concurrently overseeing multiple headquarters and divisions. Additionally, some positions of Managing Executive Officers and Executive Officers will be revised, clarifying roles such as Head of Sustainability Promotion and Head of EHS Promotion. These personnel changes aim to promote management strategies and strengthen the organization, contributing to the company’s sustainable growth.
